MELBOURNE, Australia and INDIANAPOLIS, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) will participate in the upcoming UBS Global Healthcare Conference in Palm Beach, FL (U.S.) and in the Jefferies Global Healthcare Conference in London (UK). Kevin Richardson, Chief Executive Officer, Precision Medicine will take part in a fireside chat with UBS on Monday, November 10, 2025 at 12.30pm EST (Tuesday, Nov 11 at 4:30am AEDT). Richard Valeix, Chief Executive Offi ...

Company Overview - Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing therapeutic and diagnostic radiopharmaceuticals and associated medical technologies [5] - The company is headquartered in Melbourne, Australia, with international operations in the United States, Brazil, Canada, Europe (Belgium and Switzerland), and Japan [5] - Telix aims to address significant unmet medical needs in oncology and rare diseases through its portfolio of clinical and commercial stage products [5] Investor Day Announcement - Telix will host an Investor Day on June 11, 2025, in New York City, focusing on growth opportunities in its commercial and clinical portfolio [1][2] - The event will feature presentations from key members of the Telix leadership team, including the Managing Director and Group CEO, Dr. Christian Behrenbruch, and other executives [3] - Key Opinion Leaders will also share insights on the clinical utility and opportunities for Telix's theranostic candidates during the event [3] Attendance Information - Attendance at the Investor Day is by invitation only for qualified institutional investors and analysts, and advance registration is required [4][5]